Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, Balkan S, Olson D, Olaro C, Pujades-Rodríguez M.

BMC Infect Dis. 2009 Jun 3;9:81. doi: 10.1186/1471-2334-9-81.

2.

Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment.

Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, Quillet C, Ngeth C, Ferradini L, Delfraissy JF, Laureillard D.

Antivir Ther. 2008;13(5):697-703.

3.

Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

Ahoua L, Guenther G, Rouzioux C, Pinoges L, Anguzu P, Taburet AM, Balkan S, Olson DM, Olaro C, Pujades-Rodríguez M.

BMC Pediatr. 2011 Jul 26;11:67. doi: 10.1186/1471-2431-11-67.

4.

Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda.

Bajunirwe F, Arts EJ, Tisch DJ, King CH, Debanne SM, Sethi AK.

J Int Assoc Physicians AIDS Care (Chic). 2009 Mar-Apr;8(2):139-47. doi: 10.1177/1545109709332470. Epub 2009 Mar 3.

PMID:
19258526
5.

Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.

Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG.

HIV Med. 2006 Oct;7(7):437-41.

6.

Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.

Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD; EuroSIDA Study Group.

AIDS. 2008 Oct 18;22(16):2187-98. doi: 10.1097/QAD.0b013e328310e04f.

PMID:
18832882
7.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

PMID:
19474468
8.

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.

Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, D'Arrigo R, Trotta MP, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of the HIV Genotype Resistance Test (GRT) at the National Institute for Infectious Diseases "Lazzaro Spallanzani".

Infection. 2009 Jun;37(3):203-9. doi: 10.1007/s15010-008-8142-8. Epub 2009 Mar 9.

PMID:
19274429
9.

Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.

Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, Miller E, Rutledge J, Bang H, Shealey W, D'Aquila RT, Gulick RM, Johnson WD Jr, Wright PF, Pape JW, Fitzgerald DW.

Bull World Health Organ. 2008 Dec;86(12):970-7.

10.

Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.

Zoufaly A, Fillekes Q, Hammerl R, Nassimi N, Jochum J, Drexler JF, Awasom CN, Sunjoh F, Burchard GD, Burger DM, van Lunzen J, Feldt T.

Antivir Ther. 2013;18(5):681-90. doi: 10.3851/IMP2562. Epub 2013 Mar 18.

PMID:
23502762
11.

Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study.

Helm M, Walter H, Ehret R, Schmit JC, Kurowski M, Knechten H, Korn K, Braun P, Schmidt B.

Eur J Med Res. 2007 Jun 27;12(6):231-42.

PMID:
17666312
12.

Experience of antiretroviral treatment in Georgia.

Tsertsvadze T, Bolokadze N, Gochitashvili N, Sharvadze L, Chokoshvili O, Dvali N, Gamkrelidze A, Khotenashvili L, Matic S.

Cent Eur J Public Health. 2009 Mar;17(1):25-30.

13.

Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age.

Sauvageot D, Schaefer M, Olson D, Pujades-Rodriguez M, O'Brien DP.

Pediatrics. 2010 May;125(5):e1039-47. doi: 10.1542/peds.2009-1062. Epub 2010 Apr 12.

PMID:
20385636
14.

Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand.

Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, Kittihanukul C, Kamudamas A, Tungsathapornpong A, Mundy LM.

HIV Med. 2008 May;9(5):322-5. doi: 10.1111/j.1468-1293.2008.00562.x.

15.

Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A.

J Antimicrob Chemother. 2009 Jul;64(1):109-17. doi: 10.1093/jac/dkp132. Epub 2009 Apr 27.

PMID:
19398461
16.

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.

Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group.

J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19.

17.

Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002.

Fischer A, Karasi JC, Kibibi D, Omes C, Lambert C, Uwayitu A, Hemmer R, Ende J, Schmit JC, Arendt V.

HIV Med. 2006 Jan;7(1):64-6.

18.

An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy.

Madge S, Smith CJ, Lampe F, Sabin CA, Youle M, Johnson MA, Phillips AN.

HIV Med. 2008 Apr;9(4):208-13. doi: 10.1111/j.1468-1293.2008.00548.x. Epub 2008 Feb 21.

19.

[AIDS treatment in Africa: the risk of antiretroviral resistance].

Hamers RL, Schuurman R, van Vugt M, Derdelinckx I, Rinke de Wit TF.

Ned Tijdschr Geneeskd. 2007 Dec 1;151(48):2666-71. Review. Dutch.

PMID:
18179083
20.

Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania.

Johannessen A, Garrido C, Zahonero N, Sandvik L, Naman E, Kivuyo SL, Kasubi MJ, Gundersen SG, Bruun JN, de Mendoza C.

Clin Infect Dis. 2009 Sep 15;49(6):976-81. doi: 10.1086/605502.

PMID:
19663598

Supplemental Content

Support Center